Akmika 250mg Injection
Marketer
Global Care
Salt Composition
Amikacin (250mg)
Overview Akmika 250mg Injection
Cefazolin 250mg injection combats a broad spectrum of bacterial infections, encompassing urinary tract, bone, joint, lung (pneumonia), brain, and bloodstream infections, among others. Prophylactic use is also indicated in hospitalized individuals to prevent infection. Its mechanism involves inhibiting bacterial growth. Administered intravenously (IV infusion) or intramuscularly by a healthcare professional, self-administration is strictly prohibited. Adherence to the prescribed dosage schedule is crucial; omitting doses or prematurely discontinuing treatment risks recurrence or exacerbation of infection. Commonly reported side effects include injection site reactions and elevated blood urea nitrogen. Persistent side effects or treatment inefficacy warrant medical consultation. High-dose therapy may induce balance impairment, nephrotoxicity, and ototoxicity. Strict adherence to the physician's instructions is essential, including potential monitoring via kidney function tests, audiometry, and urinalysis. Pregnancy contraindicates its use; disclose pregnancy, pregnancy plans, or breastfeeding to your doctor.
Uses of Akmika 250mg Injection
Infections caused by bacteria
Major Benefits of Akmika 250mg Injection:
The medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
Common Side effects of Akmika 250mg Injection:
- Increased blood urea
- Injection site reactions (pain, swelling, redness)
How to use Akmika 250mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.
How Akmika 250mg Injection works:
Akmika 250mg Injection is a bacterial growth inhibitor. Its antibiotic action halts the production of vital bacterial proteins, thus disrupting essential cellular processes.
SAFETY ADVICE
AlcoholSAFE
Ingestion of alcohol alongside Akmika 250mg Injection presents no known adverse reactions.
PregnancyCONSULT YOUR DOCTOR
Administering Akmika 250mg Injection during pregnancy poses a confirmed risk to fetal development and is therefore contraindicated. Nevertheless, in exceptional circumstances involving life-threatening conditions, a physician might exceptionally prescribe it when the potential advantages outweigh the inherent dangers. Physician consultation is mandatory.
Breast feedingSAFE IF PRESCRIBED
The injectable medication Akmika, 250mg, poses no known breastfeeding risk. Research in humans indicates minimal drug transfer to breast milk, presenting negligible infant harm.
DrivingUNSAFE
The administration of Akmika 250mg Injection can induce drowsiness, blurred vision, and dizziness, potentially impairing alertness. Driving should be avoided if these effects are experienced.
KidneyCAUTION
Patients with kidney impairment should use Akmika 250mg Injection cautiously; dosage modification may be necessary. Physician consultation is advised.
LiverSAFE IF PRESCRIBED
Akmika 250mg Injection is likely safe for individuals with hepatic impairment. Available evidence indicates dose modification may be unnecessary; however, medical consultation is recommended.
What if you forget to take Akmika 250mg Injection :
Omit a scheduled Akmika 250mg Injection? Seek your physician's advice.
Facts to Know About Akmika 250mg Injection
| Label | Value |
|---|---|
| Chemical Classification | Aminoglycoside antibiotics |
| Developing Habits | No. |
| Type of Therapy | Antimicrobials |
| Action Class | Aminoglycoside antibiotics |
3,018 People bought this recently